AIMC Topic: Hyperthermic Intraperitoneal Chemotherapy

Clear Filters Showing 1 to 4 of 4 articles

Predicting Postoperative Infection After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy with Splenectomy.

Annals of surgical oncology
BACKGROUND: Hematologic changes after splenectomy and hyperthermic intraperitoneal chemotherapy (HIPEC) can complicate postoperative assessment of infection. This study aimed to develop a machine-learning model to predict postoperative infection afte...

A machine learning approach for predicting textbook outcome after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

World journal of surgery
INTRODUCTION: Peritoneal carcinomatosis is considered a late-stage manifestation of neoplastic diseases. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) can be an effective treatment for these patients. However, the p...

National Guidelines for Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Peritoneal Malignancies: A Worldwide Systematic Review and Recommendations of Strength Analysis.

Annals of surgical oncology
BACKGROUND: National guidelines (GLs) for surgical cytoreduction (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in the management of peritoneal malignancies (PMs) vary across countries, scientific societies, and government agencies. This...

Predicting Severe Postoperative Complications after CRS-HIPEC: An Externally Validated Machine-Learning Tool.

World journal of surgery
INTRODUCTION: Current decision support tools designed to predict postoperative complications, following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC), are limited by small sample sizes and lack of external validatio...